Stockscreener 앱 받기
3.72
0.95%
0.035
전일 마감가:
$3.685
열려 있는:
$3.65
하루 거래량:
3.02M
Relative Volume:
0.65
시가총액:
$977.01M
수익:
$194.75M
순이익/손실:
$-51.26M
주가수익비율:
-13.29
EPS:
-0.28
순현금흐름:
$-23.38M
1주 성능:
+4.49%
1개월 성능:
+4.20%
6개월 성능:
+66.07%
1년 성능:
+188.37%
1일 변동 폭
$3.6213
$3.79
1주일 범위
$3.47
$3.81
52주 변동 폭
$1.07
$4.0787
Akebia Therapeutics Inc Stock (AKBA) Company Profile
명칭
Akebia Therapeutics Inc
전화
617-871-2098
주소
245 FIRST STREET, CAMBRIDGE, MA
AKBA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AKBA
Akebia Therapeutics Inc
|
3.72 | 967.81M | 194.75M | -51.26M | -23.38M | -0.28 |
|
ZTS
Zoetis Inc
|
147.38 | 64.91B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.16 | 43.33B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.66 | 42.36B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.38 | 17.72B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
294.28 | 12.42B | 2.99B | 1.21B | 1.13B | 25.06 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-04 | 재개 | H.C. Wainwright | Buy |
| 2025-04-28 | 개시 | Leerink Partners | Outperform |
| 2025-04-01 | 개시 | Jefferies | Buy |
| 2023-11-29 | 재개 | BTIG Research | Buy |
| 2023-08-28 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2023-05-31 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-03-31 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-03-31 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-03-31 | 다운그레이드 | Needham | Buy → Hold |
| 2022-03-31 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-03-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-01-29 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2019-11-14 | 재확인 | Needham | Buy |
| 2019-08-06 | 재확인 | H.C. Wainwright | Buy |
| 2019-07-11 | 재확인 | H.C. Wainwright | Buy |
| 2019-05-02 | 개시 | JP Morgan | Overweight |
| 2019-03-20 | 개시 | Citigroup | Neutral |
| 2018-09-07 | 재개 | Morgan Stanley | Equal-Weight |
| 2018-08-10 | 재확인 | Needham | Buy |
| 2018-06-06 | 재확인 | H.C. Wainwright | Buy |
| 2017-12-19 | 개시 | Piper Jaffray | Overweight |
| 2017-12-07 | 개시 | BTIG Research | Buy |
| 2017-09-15 | 개시 | RBC Capital Mkts | Sector Perform |
| 2017-07-10 | 재확인 | H.C. Wainwright | Buy |
| 2017-04-27 | 재확인 | H.C. Wainwright | Buy |
| 2017-04-27 | 재확인 | Needham | Buy |
| 2016-12-27 | 재확인 | H.C. Wainwright | Buy |
| 2016-12-20 | 재확인 | JMP Securities | Mkt Outperform |
| 2016-11-15 | 개시 | Aegis Capital | Buy |
| 2016-09-29 | 개시 | Brean Capital | Buy |
| 2016-03-16 | 재확인 | Needham | Buy |
| 2016-01-21 | 개시 | Credit Suisse | Neutral |
모두보기
Akebia Therapeutics Inc 주식(AKBA)의 최신 뉴스
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Akebia Therapeutics Awards $880K Worth of Stock Options in Strategic New Employee Package - Stock Titan
Order Book Volume Tilts Bullish on Akebia Therapeutics Inc.Entry Zone Strategy for Consistent Profit Shared - metal.it
Are Medical Stocks Lagging Akebia Therapeutics (AKBA) This Year? - Yahoo Finance
When is Akebia Therapeutics Inc. stock expected to show significant growthTop Growth Trend Scanner With High Returns - jammulinksnews.com
Would Akebia Therapeutics (NASDAQ:AKBA) Be Better Off With Less Debt? - 富途牛牛
What are analysts’ price targets for Akebia Therapeutics Inc. in the next 12 monthsAdvanced Screener Ideas For Every Investor - jammulinksnews.com
Akebia Therapeutics to Report Second Quarter 2025 Financial Results and Discuss Recent Business Highlights - 富途牛牛
Should I hold or sell Akebia Therapeutics Inc. stock in 2025Market Forecast Opportunities For Beginners - jammulinksnews.com
How to monitor Akebia Therapeutics Inc. with trend dashboardsEarnings Play Trade Plan With Alerts Shared - metal.it
Akebia Therapeutics (AKBA.O) Sees Sharp Intraday Move—What’s Really Behind the Surge? - AInvest
Why Akebia Therapeutics Inc. stock attracts strong analyst attentionLow Risk Stock Strategies - beatles.ru
Akebia Therapeutics (AKBA.O) Sees Sharp Intraday Spike — But No Clear Fundamental Trigger - AInvest
Akebia Therapeutics (AKBA.O) Sees Sharp Intraday Move – But No Fundamental Catalyst - AInvest
Akebia Therapeutics Inc. Moves Into Overbought Range Analysts CautiousTriple Digit Growth Focused Trade Plan Reviewed - metal.it
Trading Bots Trigger Alerts on Akebia Therapeutics Inc. ActivityTriple Digit Return Stock Predictions Released - metal.it
Applying big data sentiment scoring on Akebia Therapeutics Inc.Entry Alert With Low Drawdown Strategy Noted - metal.it
Published on: 2025-07-28 05:33:13 - jammulinksnews.com
How does Akebia Therapeutics Inc. generate profit in a changing economyFree Stock Index Interpretation - jammulinksnews.com
What is the dividend policy of Akebia Therapeutics Inc. stockNavigate market shifts with confidence - jammulinksnews.com
Is Akebia Therapeutics Inc. a growth stock or a value stockAchieve exceptional returns with expert guidance - jammulinksnews.com
What makes Akebia Therapeutics Inc. stock price move sharplyDiscover stocks with explosive upside potential - jammulinksnews.com
How many analysts rate Akebia Therapeutics Inc. as a “Buy”Discover stocks with superior performance - jammulinksnews.com
Is it the right time to buy Akebia Therapeutics Inc. stockRecord-setting profit potential - jammulinksnews.com
Akebia Rides Vafseo Launch To A Strong Year - Finimize
How Interest Rate Changes Impact Akebia Therapeutics Inc. Stock PerformanceDefensive Stock Picks with Upside - metal.it
Akebia Therapeutics (AKBA) Kidney Therapy Vafseo Gaining Market Share - MSN
H.C. Wainwright Rates Akebia Therapeutics (AKBA) Stock Buy - Insider Monkey
What drives Akebia Therapeutics Inc. stock priceFree Capital Allocation Plans - PrintWeekIndia
How Akebia Therapeutics Inc. stock reacts to Fed policy changesRapidly growing investment returns - jammulinksnews.com
Is Akebia Therapeutics Inc. a good long term investmentConsistent high-yield stocks - Autocar Professional
Is Akebia Therapeutics Inc. stock overhyped or has real potentialHigh-yield growth strategies - jammulinksnews.com
What analysts say about Akebia Therapeutics Inc. stockFree Consultation - Autocar Professional
Akebia Therapeutics Inc. Stock Analysis and ForecastFast-track wealth growth - jammulinksnews.com
Akebia Therapeutics Inc (AKBA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.87%
0.80%
자본화:
|
볼륨(24시간):